trial · primary record
Pirtobrutinib
Mantle Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 50 |
| Primary completion | 2029-02-28 |
| Primary endpoint | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
| Registry ID | NCT06522386 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:04.122Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06522386
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pirtobrutinib · approval
- Pirtobrutinib · compound